Cargando…

Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China

BACKGROUND: Coronavirus Disease 2019 (COVID-19) is an emerging and rapidly evolving disease, with no recommended effective anti-coronavirus drug treatment. Traditional Chinese Patent Medicines (CPMs) have, however, been widely used to treat COVID-19 in China, and a number of clinical practice result...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Wei, Fan, Zheng, Chu, Yanqi, Wang, Haizheng, Yang, Ying, Wu, Li, Sun, Nan, Sun, Ge, Shen, Yuqiao, Lin, Xiaolan, Guo, Guiming, Xi, Shengyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396557/
https://www.ncbi.nlm.nih.gov/pubmed/32848729
http://dx.doi.org/10.3389/fphar.2020.01066
_version_ 1783565609439592448
author Zhuang, Wei
Fan, Zheng
Chu, Yanqi
Wang, Haizheng
Yang, Ying
Wu, Li
Sun, Nan
Sun, Ge
Shen, Yuqiao
Lin, Xiaolan
Guo, Guiming
Xi, Shengyan
author_facet Zhuang, Wei
Fan, Zheng
Chu, Yanqi
Wang, Haizheng
Yang, Ying
Wu, Li
Sun, Nan
Sun, Ge
Shen, Yuqiao
Lin, Xiaolan
Guo, Guiming
Xi, Shengyan
author_sort Zhuang, Wei
collection PubMed
description BACKGROUND: Coronavirus Disease 2019 (COVID-19) is an emerging and rapidly evolving disease, with no recommended effective anti-coronavirus drug treatment. Traditional Chinese Patent Medicines (CPMs) have, however, been widely used to treat COVID-19 in China, and a number of clinical practice results have shown them to have a significant role in its treatment. Consequently, numerous guidelines and expert consensus have recommended the use of CPMs to treat COVID-19. AIM OF THE STUDY: The objectives of this review are to provide up-to-date information on the pharmacology and clinical research on CPMs in the treatment of COVID-19, discuss the research findings, and to better guide clinical application and scientific research on CPMs in the treatment of COVID-19. METHODS: The frequencies of CPM recommendations by guidelines and expert consensus for treatment of COVID-19 in China were ranked. This report identifies the top 10 CPMs, which include Huoxiang Zhengqi capsule (HXZQC), Lianhua Qingwen capsule (LHQWC), Jinhua Qinggan granule (JHQGG), Shufeng Jiedu capsule (SFJDC), Tanreqing injection (TRQI), Xiyanping injection (XYPI), Xuebijing injection (XBJI), Shenfu injection (SFI), Shengmai injection (SMI), and Angong Niuhuang pill (AGNHP). Relevant studies from 2000 to 2020 on these top 10 CPMs, covering usage, dosage, mechanism, curative effect, and precautions, were collected from pharmacopoeia, reports, and theses via library and digital databases (including PubMed, CNKI, Google Scholar, Web of Science, and Elsevier). RESULTS: The properties of the top 10 CPMs included antiviral, antibacterial, anti-inflammatory, antipyretic and analgesic, anti-acute lung injury, anti-shock, immune regulation, and enhancement of pulmonary function. In addition, clinical research results and Chinese treatment data showed that the CPMs had good therapeutic efficacy in the treatment of COVID-19, and adverse reactions were minimal. CONCLUSIONS: Knowledge of the characteristics of the top 10 CPMs and precautions that should be taken may help clinicians to rationally improve therapeutic efficacy, and promote the role of Chinese Medicine in the control of the COVID-19 global epidemic.
format Online
Article
Text
id pubmed-7396557
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73965572020-08-25 Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China Zhuang, Wei Fan, Zheng Chu, Yanqi Wang, Haizheng Yang, Ying Wu, Li Sun, Nan Sun, Ge Shen, Yuqiao Lin, Xiaolan Guo, Guiming Xi, Shengyan Front Pharmacol Pharmacology BACKGROUND: Coronavirus Disease 2019 (COVID-19) is an emerging and rapidly evolving disease, with no recommended effective anti-coronavirus drug treatment. Traditional Chinese Patent Medicines (CPMs) have, however, been widely used to treat COVID-19 in China, and a number of clinical practice results have shown them to have a significant role in its treatment. Consequently, numerous guidelines and expert consensus have recommended the use of CPMs to treat COVID-19. AIM OF THE STUDY: The objectives of this review are to provide up-to-date information on the pharmacology and clinical research on CPMs in the treatment of COVID-19, discuss the research findings, and to better guide clinical application and scientific research on CPMs in the treatment of COVID-19. METHODS: The frequencies of CPM recommendations by guidelines and expert consensus for treatment of COVID-19 in China were ranked. This report identifies the top 10 CPMs, which include Huoxiang Zhengqi capsule (HXZQC), Lianhua Qingwen capsule (LHQWC), Jinhua Qinggan granule (JHQGG), Shufeng Jiedu capsule (SFJDC), Tanreqing injection (TRQI), Xiyanping injection (XYPI), Xuebijing injection (XBJI), Shenfu injection (SFI), Shengmai injection (SMI), and Angong Niuhuang pill (AGNHP). Relevant studies from 2000 to 2020 on these top 10 CPMs, covering usage, dosage, mechanism, curative effect, and precautions, were collected from pharmacopoeia, reports, and theses via library and digital databases (including PubMed, CNKI, Google Scholar, Web of Science, and Elsevier). RESULTS: The properties of the top 10 CPMs included antiviral, antibacterial, anti-inflammatory, antipyretic and analgesic, anti-acute lung injury, anti-shock, immune regulation, and enhancement of pulmonary function. In addition, clinical research results and Chinese treatment data showed that the CPMs had good therapeutic efficacy in the treatment of COVID-19, and adverse reactions were minimal. CONCLUSIONS: Knowledge of the characteristics of the top 10 CPMs and precautions that should be taken may help clinicians to rationally improve therapeutic efficacy, and promote the role of Chinese Medicine in the control of the COVID-19 global epidemic. Frontiers Media S.A. 2020-07-17 /pmc/articles/PMC7396557/ /pubmed/32848729 http://dx.doi.org/10.3389/fphar.2020.01066 Text en Copyright © 2020 Zhuang, Fan, Chu, Wang, Yang, Wu, Sun, Sun, Shen, Lin, Guo and Xi http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhuang, Wei
Fan, Zheng
Chu, Yanqi
Wang, Haizheng
Yang, Ying
Wu, Li
Sun, Nan
Sun, Ge
Shen, Yuqiao
Lin, Xiaolan
Guo, Guiming
Xi, Shengyan
Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China
title Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China
title_full Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China
title_fullStr Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China
title_full_unstemmed Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China
title_short Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China
title_sort chinese patent medicines in the treatment of coronavirus disease 2019 (covid-19) in china
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396557/
https://www.ncbi.nlm.nih.gov/pubmed/32848729
http://dx.doi.org/10.3389/fphar.2020.01066
work_keys_str_mv AT zhuangwei chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina
AT fanzheng chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina
AT chuyanqi chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina
AT wanghaizheng chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina
AT yangying chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina
AT wuli chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina
AT sunnan chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina
AT sunge chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina
AT shenyuqiao chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina
AT linxiaolan chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina
AT guoguiming chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina
AT xishengyan chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina